FDA Grants Priority Review to sBLA of Ultomiris for Treatment of aHUS
The U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) for Alexion‘s Ultomiris (ravulizumab-cwvz) for the treatment of patients with atypical hemolytic uremic syndrome (aHUS). aHUSÂ is caused by the progressive destruction of red…